[STAR™ – radiofrequency ablation system for vertebral metastasis]
Comite d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT)
Record ID 32015001193
French
Authors' objectives:
The CEDIT assessed the clinical value of the STAR™ (company D-FINE) radiofrequency ablation system intended to treat vertebral metastasis.
Authors' recommendations:
In patients for whom radiofrequency ablation is indicated but for which this procedure would be contraindicated by the proximity of the nervous system, the STAR™ device could be a useful alternative. Despite the high cost of the device and the procedure, the scarcity of indications suggests a low budgetary impact.
Therefore, the CEDIT recommends:
- that the STAR ™ device be made available to radiology and interventional neuroradiology departments of AP-HP having experience in the management of vertebral metastases.
- The CEDIT also calls for a clinical study whose methodology and objectives remain to be established.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://cedit.aphp.fr/star-radiofrequency-ablation-system-vertebral-metastasis/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
MeSH Terms
- Humans
- Neoplasms
- Spine
- Nervous System
- Radiology
Contact
Organisation Name:
Cellule Innovation of the AP-HP
Copyright:
Comite d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.